+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06189391

Open-Label Study Evaluating Safety and Effectiveness of MK-1045 IV Infusion in Adults With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Led by MSD R&D (China) Co., Ltd. · Updated on 2026-10-29

100

Participants Needed

15

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating new treatments for people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma B-NHL, a cancer affecting the lymphatic system that causes enlarged lymph nodes or organs in the belly or chest. This study focuses on MK-1045, an immunotherapy designed to help the immune system fight this type of cancer. The trial aims to evaluate the safety, tolerability, and proper dosing of MK-1045, as well as its preliminary effectiveness in treating relapsed or refractory B-NHL. Participants will receive MK-1045 through intravenous infusions once a week for three consecutive weeks, followed by one week off, forming a four-week cycle. This treatment continues for up to 12 months or until discontinuation or death. There are two dosing schedules a fixed dose and a step-up dose with priming, both given weekly during the three-week cycles. The study is open-label and non-randomized, meaning participants and researchers know the treatment being given. During the study, participants will be closely monitored through various assessments including safety evaluations for adverse events and dose-limiting toxicities, blood tests to measure drug levels and immune cell responses, and imaging scans to assess tumor changes. Researchers will also track treatment responses and progression-free survival over about 15 months. Participants may be involved in regular visits for infusions and evaluations throughout their participation, which can last up to a year or more depending on treatment continuation.

CONDITIONS

Brief Title

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here